| Literature DB >> 14563122 |
Heinrich Kovar1, Josef Ban, Sarka Pospisilova.
Abstract
Existing data identify EWS-FLI1 as indispensable for sustained Ewing's sarcoma growth and as the ideal therapeutic target in this disease. The siRNA may hold great promises as a fusion gene specific agent. RNAi mediated suppression of EWS-FLI1 is likely to result in an altered tumor cell phenotype including changes in chemosensitivity, and a restored differentiation potential. Thus, RNAi may serve as an adjuvant to chemotherapy. As a therapeutic means however, RNAi is hampered by limitations in the delivery of the agent and emergence of resistant clones. In vitro suppression of EWS-FLI1 expression will allow to define the phenotypic characteristics of dormant tumor cells that may give rise to late relapses, enabling improved diagnosis and treatment even of minimal residual disease.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14563122 DOI： 10.1016/s1044-579x(03)00041-5
Source DB: PubMed Journal: Semin Cancer Biol ISSN： 1044-579X Impact factor: 15.707